An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

Launched by BAYER · Oct 31, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how well different treatments work for adults with liver cancer that cannot be surgically removed, known as unresectable hepatocellular carcinoma (uHCC), after they have received a first-line treatment combining two drugs called atezolizumab and bevacizumab, or another similar combination. The main goal is to gather information on how long participants live and how their cancer responds to the next treatment they receive after the initial therapy. Researchers will collect data from patients' medical records and during routine doctor visits to understand the effectiveness of these subsequent treatments.

To participate, individuals must be at least 18 years old and have received the first-line treatment mentioned above. They should also have a confirmed diagnosis of uHCC and be starting a new second-line treatment based on their doctor's recommendations. Participants won’t need any extra visits or tests specifically for the study; the researchers will simply observe their progress during standard care over the next few years. This study aims to improve knowledge about the best treatment options for patients after initial therapies, which could ultimately lead to better outcomes for those with this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients, ≥ 18 years of age on the day of signing informed consent.
• • Confirmed diagnosis of uHCC, treated in a first-line setting with AB or another approved 1L-IO combo therapy.
• • Decision to initiate treatment with a second-line systemic treatment was made as per investigator's routine treatment practice prior to study enrollment.
• • Signed informed consent or (for patients under legal age) signed informed assent by the patient (where applicable) and signed informed consent by parents / legal guardian.
• • No participation in an investigational program with interventions outside of routine clinical practice.
• Exclusion Criteria:
• • - Not applicable